Matching articles for "mNEXSPIKE"
COVID-19 Update: 2025-2026 Vaccine Formulations and Recommendations
The Medical Letter on Drugs and Therapeutics • October 13, 2025; (Issue 1739)
The FDA has licensed new 2025-2026 formulations
of the mRNA COVID-19 vaccines manufactured by
Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax,
mNEXSPIKE) and the adjuvanted protein subunit
COVID-19...
The FDA has licensed new 2025-2026 formulations
of the mRNA COVID-19 vaccines manufactured by
Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax,
mNEXSPIKE) and the adjuvanted protein subunit
COVID-19 vaccine manufactured by Novavax
(Nuvaxovid). The new formulations are indicated
for use in all adults ≥65 years old and in persons
6 months (Spikevax), 5 years (Comirnaty), or 12
years (mNEXSPIKE, Nuvaxovid) through 64 years old
who are at high risk for severe COVID-19 because
of an underlying condition. An Emergency Use
Authorization allowing administration of the Pfizer
vaccine to children 6 months through 4 years old has
been withdrawn.
COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19
The Medical Letter on Drugs and Therapeutics • July 21, 2025; (Issue 1733)
The FDA has licensed mNEXSPIKE (Moderna), an
mRNA vaccine, for prevention of COVID-19 in adults
≥65 years old and in persons 12-64 years old who
have a condition that puts them at high risk for
severe...
The FDA has licensed mNEXSPIKE (Moderna), an
mRNA vaccine, for prevention of COVID-19 in adults
≥65 years old and in persons 12-64 years old who
have a condition that puts them at high risk for
severe outcomes from COVID-19. Spikevax, the
original Moderna mRNA COVID-19 vaccine, remains
in production2; it is licensed for use in persons
≥12 years old and is available under an Emergency
Use Authorization (EUA) for children 6 months to
11 years old.